Elevated systemic immunity-inflammation index as a predictor of mortality from severe COVID-19

Abstract

Objective: To analyze whether elevated systemic immunity-inflammation index (IIIS) is a predictor of mortality due to severe COVID-19. Material and Methods: A retrospective cohort study was conducted with the medical records of patients with severe COVID-19 at the Temporary Care and Isolation Center of Bagua, Amazonas, between March 2020 and December 2021. Results: There was no significant difference between age and sex, both for IIIS values and mortality due to severe COVID-19. Lung involvement was greater than 75% in 49.1% of the deceased and 19.6% in the survivors (RR: 1.54; p=0.001). Hypoalbuminemia was more frequent in the deceased than in the living (45.6% and 25.5%, respectively) and was a risk factor (RR: 1.48; p=0.030). IIIS greater than 1,835 was found to be an independent risk factor for mortality due to severe COVID-19 (RRa: 1.726; 95%CI: 1.067-2.792), as well as obesity (RRa: 1.578; 95%CI: 1.06-2.58) and pulmonary involvement (RRa: 1.83; 95%CI: 1.0445-3.205). Conclusion: IIIS greater than 1,835 is a predictor of mortality in patients with severe COVID-19.